Biohaven Pharm (NYSE:BHVN) CFO James Engelhart sold 30,538 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $26.58, for a total value of $811,700.04. Following the completion of the transaction, the chief financial officer now directly owns 25,176 shares of the company’s stock, valued at $669,178.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Biohaven Pharm (BHVN) opened at $25.36 on Friday. Biohaven Pharm has a 12 month low of $17.00 and a 12 month high of $39.51.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/17/insider-selling-biohaven-pharm-bhvn-cfo-sells-811700-04-in-stock.html.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Biohaven Pharm from a “sell” rating to a “hold” rating in a report on Friday, September 8th. BidaskClub upgraded Biohaven Pharm from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price (up from $30.00) on shares of Biohaven Pharm in a research note on Wednesday, September 13th. Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 target price on shares of Biohaven Pharm in a research note on Tuesday, September 12th. Finally, Morgan Stanley upped their target price on Biohaven Pharm from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Biohaven Pharm currently has a consensus rating of “Buy” and a consensus target price of $40.80.

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new position in Biohaven Pharm in the third quarter valued at $119,000. Nationwide Fund Advisors acquired a new position in Biohaven Pharm in the third quarter valued at $214,000. American International Group Inc. acquired a new position in Biohaven Pharm in the third quarter valued at $251,000. State of Wisconsin Investment Board acquired a new position in Biohaven Pharm in the third quarter valued at $262,000. Finally, Deschutes Portfolio Strategy LLC acquired a new position in Biohaven Pharm in the third quarter valued at $374,000. Hedge funds and other institutional investors own 44.03% of the company’s stock.

About Biohaven Pharm

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharm (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharm and related companies with MarketBeat.com's FREE daily email newsletter.